市場調査レポート
商品コード
1242103

CAR T細胞療法の世界市場

CAR T-cell Therapy

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 179 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
CAR T細胞療法の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

CAR T細胞療法の世界市場は2030年までに96億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に20億米ドルと推定されるCAR T細胞療法の世界市場は、2022年から2030年にかけてCAGR 21.9%の成長を遂げ、2030年までに96億米ドルの規模に達すると予測されます。本レポートで分析したセグメントの1つであるDLBCLは、CAGR18.7%を記録し、分析期間終了時には46億米ドルに達すると予測されます。パンデミック後の回復を考慮し、ALLセグメントの成長は、今後8年間のCAGRが25.6%に修正されました。

米国市場は6億1,050万米ドル、中国はCAGR21.4%の成長が予測されています。

米国のCAR T細胞療法市場は、2022年に6億1,050万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが21.4%となり、2030年には17億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ18.9%と18.7%の成長が予測されています。欧州では、ドイツがCAGR15.3%で成長すると予測されています。

調査対象企業の例

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10884

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global CAR T-cell Therapy Market to Reach $9.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for CAR T-cell Therapy estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$9.6 Billion by 2030, growing at aCAGR of 21.9% over the period 2022-2030. DLBCL, one of the segments analyzed in the report, is projected to record 18.7% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ALL segment is readjusted to a revised 25.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $610.5 Million, While China is Forecast to Grow at 21.4% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$610.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.9% and 18.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Select Competitors (Total 12 Featured) -

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CAR T-cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for DLBCL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World 8-Year Perspective for DLBCL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for ALL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for ALL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for MM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for MM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CLL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for CLL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for FL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for FL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • CANADA
    • TABLE 16: Canada Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: Canada 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • JAPAN
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 18: Japan Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Japan 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • CHINA
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: China 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • EUROPE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 22: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: Europe 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 24: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • FRANCE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 26: France Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: France 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • GERMANY
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 28: Germany Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Germany 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • ITALY
    • TABLE 30: Italy Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Italy 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • UNITED KINGDOM
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 32: UK Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: UK 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Rest of Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • ASIA-PACIFIC
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Asia-Pacific 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 38: Rest of World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Rest of World 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030

IV. COMPETITION